New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

BioXcel Therapeutics

Contributing Author

Recent Articles by BioXcel Therapeutics

Sep-18	BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements BTAI GlobeNewswire
Sep-10	BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Sep-04	BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference BTAI GlobeNewswire
Aug-27	UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI BTAI GlobeNewswire
Aug-27	BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI BTAI GlobeNewswire
Aug-26	BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 BTAI GlobeNewswire
Aug-19	BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Aug-18	BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Aug-13	BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. "HCW@Home" Series BTAI GlobeNewswire
Aug-12	BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates BTAI GlobeNewswire
Aug-11	BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference BTAI GlobeNewswire
Aug-06	BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies BTAI GlobeNewswire
Aug-01	BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
Jul-21	BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI BTAI GlobeNewswire
Jul-01	BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
May-27	BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia BTAI GlobeNewswire
May-27	BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement BTAI GlobeNewswire
May-12	BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update BTAI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.